FDA Approves Inluriyo-Verzenio Breast Cancer Combination
The FDA approved Eli Lilly’s Inluriyo and Verzenio combination for certain adults with advanced or metastatic ER-positive, HER2-negative breast cancer carrying an ESR1 mutation.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Eli Lilly announced on September 18 that the FDA had approved Inluriyo, whose active ingredient is imlunestrant, in combination with Verzenio, or abemaciclib. The approval applies after disease progression following at least one line of endocrine therapy.
Who falls within the approval
The FDA defined the eligible population as adults with locally advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative and carries an ESR1 mutation. The regimen combines two oral cancer medicines.
The approval concerns a molecularly and clinically defined group rather than every person with breast cancer. Eligibility depends on the cancer subtype, ESR1 mutation status, stage and progression after prior endocrine therapy.
What patients should clarify
FDA approval identifies a treatment option for the specified population, but it does not determine an individual patient’s expected benefit or risks. A treating oncology team must assess whether the approved criteria match the patient’s diagnosis and treatment history.
Frequently asked questions
Who qualifies for the Inluriyo and Verzenio combination?
The FDA approval covers adults with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. A clinician must confirm whether an individual patient meets these criteria.
Is this combination approved for every type of breast cancer?
No. The FDA approval is limited to the specified receptor profile, ESR1 mutation status, disease stage and prior-treatment setting.
Are Inluriyo and Verzenio taken by mouth?
Yes. The approved combination uses two oral cancer medicines: imlunestrant and abemaciclib.
Questions for the oncology appointment
- Is my breast cancer ER-positive and HER2-negative?
- Has testing identified an ESR1 mutation?
- Does my treatment history meet the FDA-approved criteria for this combination?
- How should the potential benefits and risks be assessed in my case?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
